Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer | Zendy

Kathleen N. Moore | Zendy; Nicoletta Colombo | Zendy; Giovanni Scambia | Zendy; ByoungGie Kim | Zendy; Ana Oaknin | Zendy; Michael Friedlander | Zendy; Alla Lisyanskaya | Zendy; Anne Floquet | Zendy; Alexandra Léary | Zendy; Gabe S. Sonke | Zendy; Charlie Gourley | Zendy; Susana Banerjee | Zendy; Amit M. Oza | Zendy; Antonio GonzálezMartín | Zendy; Carol Aghajanian | Zendy; William H. Bradley | Zendy; Cara Mathews | Zendy; Joyce F. Liu | Zendy; Elizabeth Lowe | Zendy; Ralph Bloomfield | Zendy; Paul DiSilvestro | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer

Author(s) -

Kathleen N. Moore,

Nicoletta Colombo,

Giovanni Scambia,

ByoungGie Kim,

Ana Oaknin,

Michael Friedlander,

Alla Lisyanskaya,

Anne Floquet,

Alexandra Léary,

Gabe S. Sonke,

Charlie Gourley,

Susana Banerjee,

Amit M. Oza,

Antonio GonzálezMartín,

Carol Aghajanian,

William H. Bradley,

Cara Mathews,

Joyce F. Liu,

Elizabeth Lowe,

Ralph Bloomfield,

Paul DiSilvestro

Publication year - 2018

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1810858

Subject(s) - olaparib , medicine , ovarian cancer , oncology , chemotherapy , disease , parp inhibitor , cancer , maintenance therapy , gynecology , poly adp ribose polymerase , polymerase , biology , enzyme , biochemistry

Most women with newly diagnosed advanced ovarian cancer have a relapse within 3 years after standard treatment with surgery and platinum-based chemotherapy. The benefit of the oral poly(adenosine diphosphate-ribose) polymerase inhibitor olaparib in relapsed disease has been well established, but the benefit of olaparib as maintenance therapy in newly diagnosed disease is uncertain.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research